WO2009019138A2 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives - Google Patents
Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Download PDFInfo
- Publication number
- WO2009019138A2 WO2009019138A2 PCT/EP2008/059702 EP2008059702W WO2009019138A2 WO 2009019138 A2 WO2009019138 A2 WO 2009019138A2 EP 2008059702 W EP2008059702 W EP 2008059702W WO 2009019138 A2 WO2009019138 A2 WO 2009019138A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- represented
- cortexolone
- crystalline form
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/005—Degradation of the lateral chains at position 17
Definitions
- Cortexolone derivatives in which the hydroxyl group at position C-17 ⁇ is esterified with short chain aliphatic or aromatic acids , and the derivatives of the corresponding 9,11-dehydro derivative, are known to have an antiandrogenic effect.
- EP 1421099 describes cortexolone 17 ⁇ -propionate and 9,11-dehydro-cortexolone-
- a method for obtaining the above mentioned derivatives is described by Gardi et al. (Gazz. Chim. It. 63, 43 1,1963) and in the United States patent US3152154 providing for the transformation of cortexolone, or transformation of 9,11- dehydrocortexolone, in the intermediate orthoester using orthoesters available in the market as a mixture of aprotic solvents such as cyclohexane and DMF, in presence of acid catalysis (ex. PTSA.H 2 0).
- the intermediate orthoester thus obtained can be used as is or upon purification by suspension in a solvent capable of solubilising impurities, preferably in alcohols.
- the subsequent hydrolysis in a hydroalcoholic solution, buffered to pH 4-5 preferably in acetate buffer provides the desired monoester.
- US3152154 describes how the hydrolysis of the diester in a basic environment is not convenient due to the formation of a mixture of 17 ⁇ ,21-diol, of
- an alcoho lysis reaction using a lipase from Candida as a biocatalyst can be usefully applied during the preparation of 17 ⁇ monoesters of cortexolone, or its 9,11-dehydroderivatives.
- the chemoselectivity of the special enzymatic reaction in alcoho lysis conditions opens new perspectives for preparation, at industrial level with higher yields, of 17 ⁇ -monoesters with respect to the methods already indicated in literature.
- diesters serving as a substrate for the reaction of the invention can be prepared according to the prior art, for example following the one described in
- an object of the present invention is a process for the preparation of 17 ⁇ monoesters of cortexolone, and its 9,11-dehydroderivatives, of formula I
- R is a linear or branched aliphatic or aromatic chain containing 1 to 10 carbon atoms, characterised in that a compound of formula II
- R bears the same meaning indicated above, is reacted with a compound having the formula R'OH, wherein R' is a linear chain containing 1 to 10 carbon atoms, preferably a Ci-Cs alkyl , in presence of a lipase from Candida.
- R is preferably a Ci -C 4 alkyl , even more preferably it is selected from among CH 3 , CH 3 CH 2 , CH 3 (CH 2 )2 or CH 3 (CH 2 ) 3 .
- the lipase from Candida used to catalyse the process of the present invention is preferably selected between the lipase from Candida cylindracea (CCL) and lipase from Candida antarctica of type B (CALB).
- Lipase from Candida and in particular the ones from Candida cylindracea and
- Candida antarctica are proved to be capable of selectively hydro lysing the ester function in position 21, contrary to the porcine pancreatic lipase (PPL) and to one from Pseudomonas fluorescens (PFL), which are proved to be almost inactive.
- the amount of said enzyme, calculated with respect to the initial substrate, may vary depending on the type of enzyme used.
- said enzyme is preferably used in an amount in the range of 100 to 1,000,000 U/mmol; more preferably in the range of 1,000 to 1,000,000 U/mmol in case of CCL and in the range of 100 to 100,000 U/mmol in case of CALB. Even more preferably, said enzyme is present at an amount of about 60,000 U/mmol in case of CCL and about 5,000 U/mmol in case CALB.
- the concentration of the initial diesters of formula II is preferably in the range of about 0.01 to 0.15 molar, more preferably about 0.025 molar.
- the process of the invention preferably occurs in the presence of an organic solvent, more preferably an aprotic organic solvent.
- Said solvent is then preferably selected from among toluene, acetonitrile, tetrahydrofuran, dichloromethane and/or chloroform.
- the R'OH alcohol according to the invention is preferably selected from among methanol, ethanol, butanol and/or octanol.
- Said alcohol is preferably present at a quantity in the range of about 0.5 to about
- the process according to the present invention preferably occurs under constant stirring until the initial diester of formula II is dissolved. Subsequently the enzyme used is removed for filtration, preferably filtration on Celite and the monoester of formula I is obtained through evaporation of the solvent under low pressure.
- the reaction time of the process is usually in the range of 20 to 150 hours, preferably in the range of 24 to 72 hours and the reaction temperature is preferably in the range of about 10 to 48°C, more preferably in the range of 20 to 32°C.
- 21 -diesters of cortexolone or of 9,11-dehydro-cortexolone in particular the 17 ⁇ - butanoate of 9,11-dehydrocortexolone was obtained starting from the corresponding dibutanoate preferably using the CCL enzyme and methanol as an acceptor alcohol of the acyl group.
- the concentration of the initial 9,11-dehydro derivatives is preferably in the range of 0.01 to 0.15 molar, more preferably 0.025 molar.
- reaction time is preferably in the range of 45 to 55 hours, preferably 53 hours.
- reaction temperature is preferably in the range of 10 to 48°C, more preferably in the range of 20 to 32°C.
- the process according to the present invention may optionally comprise a final step of crystallisation from an organic solvent, water, buffered aqueous solutions and/or or their mixture.
- the organic solvent of said step of crystallisation is preferably selected from among diisopropylether, terbutylmethylether, dichloromethane, ethyl acetate, hexane, acetone, ethanol, water or their mixture at any proportion.
- an object of the present invention are the crystalline forms of cortexolone 17 ⁇ -propionate and of 9,11 -cortexo lone- 17 ⁇ -butanoate.
- the crystalline form I of 17 ⁇ -propionate is preferably obtained through crystallisation from tert-butylmethylether.
- concentration of 17 ⁇ -propionate in said solvent is in the range of 0.9 to 1.1 g in 9-11 ml of tert-butylmethylether preferably Ig in 10 ml.
- Said crystalline form I is characterised by a melting point in the range of about 133 to 135°C and/or a DRX as in Fig. 1 and/or a DSC as shown in Fig. 2 and/or an IR as shown in Fig. 3.
- the crystalline form II of 17 ⁇ -propionate is preferably obtained through crystallisation from diisopropylether.
- concentration in said solvent is preferably in the range of 0.9 to 1.1 g in 54-66 ml of diisopropylether.
- the crystalline form III of 17 ⁇ -propionate is preferably obtained through crystallisation from a mixture of dichloromethane/n-hexane preferably in a ratio of about 1/30, acetone/n-hexane preferably in a ratio of about 1/8, or ethano I/water mixture preferably in a ratio of about 1/2.
- the crystalline form III obtained from dichloromethane/n-hexane has a DRX as shown in Fig. 7 and/or a DSC as shown in Fig. 8 and/or an IR as shown in Fig. 9.
- the crystalline form III obtained from acetone/n-hexane has a DRX as shown in
- the crystalline form III obtained from ethanol/water has a DRX as shown in Fig.
- the crystalline form I of 9,1 l-dehydro-17 ⁇ -cortexo lone is preferably obtained from tert-butylmethylether, diisopropylether, a dichloromethane/n-hexane mixture preferably in a ratio of 1/15 , or an acetone/n-hexane mixture preferably in a ratio of 1/5.
- the crystalline form I obtained from tert-butylmethylether has a DRX as shown in
- the crystalline form I obtained from diisopropylether has a DRX as shown in Fig.
- the crystalline form I obtained from dichloromethane/n-hexane has a DRX as shown in Fig. 22 and/or a DSC as shown in Fig. 23 and/or an IR as shown in Fig.
- the crystalline form I obtained from acetone/n-hexane has a DRX as shown in
- Table 3 shows some identification parameters and conditions for obtaining the abovementioned crystalline forms.
- the solvate crystalline form IV of 17 ⁇ -propionate is preferably obtained through crystallisation from an organic/water solvent mixture in a ratio generally in the range of 1/2 to 2/1, preferably from propylene glycol/water in a ratio of 1/1 or poly ethylengly co I/water in a ratio of 1/1.
- the solvate crystalline form IV obtained from propylene glycol/water 1/1 has a
- the crystallisation of 17 ⁇ -propionate in solvate form may occur during the formulation processes of the final pharmaceutical form, where the manufacturing process of the pharmaceutical form provides for the dissolution of the active ingredient in an organic solvent, such as for example, propylene glycol, polyethylene glycol or short-chained aliphatic alcohols, followed by the addition of water in a ratio of 1/3 to 3/1 with respect to the organic solvents used for the dissolution of the active ingredient.
- an organic solvent such as for example, propylene glycol, polyethylene glycol or short-chained aliphatic alcohols
- an object of the present invention is a pharmaceutical composition containing at least one of the crystalline forms described above in association with at least one physiologically acceptable excipient.
- compositions of the present invention can be of solid, semi- so lid, pasty or liquid form and they are preferably selected from among tablets, capsules, powders, pellets, suspensions, emulsions, solutions, creams, gel, ointment, lotions or pastes both ready to use or to be reconstituted before use.
- object of the present invention is the use, preferably for human beings, of at least one of the crystalline forms and/or solvates described above for the preparation of a medication for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages.
- an object of the present invention is the use of a liquid or semi-liquid formulation for topical administration, such as for example, cream, gel, ointment, emulsion or dispersion containing cortexolone-17 ⁇ -propionate in the range of 0.1 to 2% by weight, preferably in the range of 0.2 to 1%, in a crystalline form selected from among solvate forms I, II, III or IV, preferably in solvate form IV, both in solution and crystalline dispersion states, the latter being possibly obtained also in an extemporaneous manner by precipitation of the crystalline active ingredient upon addition of water or aqueous solution to a solution containing the same active ingredient in an organic solvent or a mixture of organic solvents, for the preparation of a medication for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or or skin appendages.
- a liquid or semi-liquid formulation for topical administration such as for example, cream, gel, ointment, emulsion or disper
- an object of the present invention is the use of a liquid or solid formulation for oral or systemic administration, such as for example, a tablet, capsule, granule or powder containing 9,l l-dehydro-cortexolone-17 ⁇ -butanoate in the dosage in the range of 4 to 65% by weight, preferably in the range of 5 to 50%, with respect to the total formulation when said total formulation has a final weight of 200 mg or in the range of 1 to 25% by weight, preferably in the range of 2 to 20%, when the total formulation has a final weight of 500 mg in a crystalline form selected between solvate forms I, or IV, for treating pathologies affecting the urogenital system, the endocrine system, the skin and/or or skin appendages.
- a liquid or solid formulation for oral or systemic administration such as for example, a tablet, capsule, granule or powder containing 9,l l-dehydro-cortexolone-17 ⁇ -butanoate in the dosage in the range of 4 to 65% by weight
- Said pathologies according to the invention are preferably selected from among acne, seborrhoeic dermatitis, androgenetic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, male contraception, polycystic ovary syndrome, control of aggressive or aberrant sexual behaviours and syndrome of precocious puberty .
- Precipitation Disslove the sample in the suitable solvent (dichloromethane, acetone, ethyl acetate or ethanol) according to the ratios indicated in table 3 and then add the solvent, hexane or water, according to the ratios indicated in table 3, maintaining the mixture, under stirring, at room temperature. Recover the precipitate by filtration using a buchner funnel and desiccate as in example 6.
- suitable solvent dichloromethane, acetone, ethyl acetate or ethanol
- the emulsion After cooling the emulsion up to about 30 0 C, add - under stirring and under negative pressure - the cortexolone 17 ⁇ -propionate solution in propylene glycol. Maintain the emulsioned cream under stirring until you obtain homogeneity, making sure the temperature remains low by means the circulation of a coolant.
- the cream contains a dispersed crystalline fraction, made up of an active ingredient in solvate crystalline form IV, formed due to the precipitation of the active ingredient itself from the glycolic solution which contained it when the latter was added to the predominantly aqueous formulation.
- the DRX spectra of the crystalline form present in the cream are indicated in Fig. 30.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL15175112T PL2966175T3 (en) | 2007-08-03 | 2008-07-24 | Pharmaceutical compositions containing cortexolone-17-alpha-propionate |
MX2014009552A MX363238B (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives. |
ES08775319.0T ES2462946T3 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process to obtain 17-alpha cortexolone propionate in crystalline form III |
BRPI0814163-0A2A BRPI0814163A2 (en) | 2007-08-03 | 2008-07-24 | PROCESS FOR PREPARATION OF COMPOUNDS, CRYSTALLINE FORM, AND PHARMACEUTICAL COMPOSITION |
RS20140233A RS53310B (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form iii |
CA2691445A CA2691445C (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
KR1020107003182A KR101495192B1 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
EP19163462.5A EP3521298A1 (en) | 2007-08-03 | 2008-07-24 | Cortexolone-17-alpha-propionate crystalline form iii and its pharmaceutical use |
CN2008800245389A CN101743316B (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of 11-deoxycortisol and/or 9, 11-dehydro derivatives thereof |
EP08775319.0A EP2173891B1 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III |
DK08775319.0T DK2173891T3 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process to obtain cortexolone 17-alpha propionate in crystalline form III |
MX2014009553A MX363701B (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives. |
US12/671,932 US8785427B2 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
EP15175112.0A EP2966175B1 (en) | 2007-08-03 | 2008-07-24 | Pharmaceutical compositions containing cortexolone-17-alpha-propionate |
MX2010001256A MX2010001256A (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives. |
JP2010518628A JP5646992B2 (en) | 2007-08-03 | 2008-07-24 | Enzymatic method for obtaining 17α-monoester of cortexolone and / or its 9,11-dehydro derivative |
RU2010107599/10A RU2482190C2 (en) | 2007-08-03 | 2008-07-24 | CRYSTALLINE FORMS OF CORTEXOLONE-17α-PROPIONATE AND METHOD FOR PREPARING THEM |
PL08775319T PL2173891T3 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III |
AU2008285784A AU2008285784B2 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
SI200831199T SI2173891T1 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III |
ZA2010/00587A ZA201000587B (en) | 2007-08-03 | 2010-01-26 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US14/073,928 US9433628B2 (en) | 2007-08-03 | 2013-11-07 | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
HRP20140421AT HRP20140421T1 (en) | 2007-08-03 | 2014-05-09 | Enzymatic process for obtaining cortexolone-17- alpha-propionate in crystalline form iii |
US14/886,774 US9486458B2 (en) | 2007-08-03 | 2015-10-19 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US15/211,087 US10166245B2 (en) | 2007-08-03 | 2016-07-15 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US15/211,094 US10159682B2 (en) | 2007-08-03 | 2016-07-15 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US16/195,083 US10716796B2 (en) | 2007-08-03 | 2018-11-19 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US16/686,738 US11207332B2 (en) | 2007-08-03 | 2019-11-18 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US17/455,538 US11938141B2 (en) | 2007-08-03 | 2021-11-18 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US18/057,031 US20230104965A1 (en) | 2007-08-03 | 2022-11-18 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001616A ITMI20071616A1 (en) | 2007-08-03 | 2007-08-03 | ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI. |
ITMI2007A001616 | 2007-08-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/671,932 A-371-Of-International US8785427B2 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
US14/073,928 Division US9433628B2 (en) | 2007-08-03 | 2013-11-07 | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009019138A2 true WO2009019138A2 (en) | 2009-02-12 |
WO2009019138A3 WO2009019138A3 (en) | 2009-10-15 |
Family
ID=40278805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/059702 WO2009019138A2 (en) | 2007-08-03 | 2008-07-24 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Country Status (25)
Country | Link |
---|---|
US (9) | US8785427B2 (en) |
EP (5) | EP2503004B1 (en) |
JP (3) | JP5646992B2 (en) |
KR (1) | KR101495192B1 (en) |
CN (3) | CN103450304B (en) |
AR (3) | AR072235A1 (en) |
AU (1) | AU2008285784B2 (en) |
BR (1) | BRPI0814163A2 (en) |
CA (3) | CA2871025C (en) |
DK (4) | DK2966175T3 (en) |
ES (4) | ES2732326T3 (en) |
HR (4) | HRP20140421T1 (en) |
HU (3) | HUE026206T2 (en) |
IT (1) | ITMI20071616A1 (en) |
LT (1) | LT2966175T (en) |
MX (4) | MX2010001256A (en) |
NZ (3) | NZ600767A (en) |
PL (4) | PL2503005T3 (en) |
PT (4) | PT2503004E (en) |
RS (4) | RS54361B1 (en) |
RU (2) | RU2482190C2 (en) |
SI (4) | SI2503005T1 (en) |
TR (1) | TR201909129T4 (en) |
WO (1) | WO2009019138A2 (en) |
ZA (2) | ZA201000587B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015091733A1 (en) | 2013-12-20 | 2015-06-25 | Cassiopea S.P.A. | CORTEXOLONE 17α-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND/OR ATROPHIC SKIN DISORDERS |
EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
EP3108879A1 (en) * | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
FR3115284A1 (en) | 2020-10-19 | 2022-04-22 | Industriale Chimica S.R.L. | METHOD FOR THE PREPARATION OF 21-(ACETYLOXY)-17-(1-OXOPROPOXY)-PREGN-4-ENE-3,20-DIONE |
IT202100008429A1 (en) | 2021-04-06 | 2022-10-06 | Farmabios Spa | Process for the preparation of cortexolone 17α-propionate and its new hydrated crystalline form |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20071616A1 (en) | 2007-08-03 | 2009-02-04 | Cosmo Spa | ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI. |
CN112028956A (en) * | 2020-09-10 | 2020-12-04 | 那路新 | Method for synthesizing 21-hydroxy-17- (1-oxopropoxy) pregn-4-ene-3,20-dione |
CN114410727B (en) * | 2022-01-25 | 2023-09-19 | 山东诺明康药物研究院有限公司 | Preparation method of clavulanone |
CN115073546A (en) * | 2022-06-01 | 2022-09-20 | 浙江神洲药业有限公司 | Preparation method of novel androgen receptor inhibitor |
CN115466301A (en) * | 2022-08-29 | 2022-12-13 | 扬州奥锐特药业有限公司 | Steroid compound, crystal form A thereof, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152154A (en) | 1961-06-24 | 1964-10-06 | Vismara Francesco Spa | 17-monoesters of 17alpha, 21-dihydroxy steroids and process for the preparation thereof |
EP1421099A1 (en) | 2001-08-10 | 2004-05-26 | Cosmo S.p.A. | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB791771A (en) | 1954-07-29 | 1958-03-12 | Merck & Co Inc | Steroid compounds |
US2985650A (en) * | 1958-05-28 | 1961-05-23 | Syntex Sa | 6alpha-ammonio-derivatives of 11-keto cortical hormones |
NL6605514A (en) * | 1966-04-25 | 1967-10-26 | ||
NL6605515A (en) * | 1966-04-25 | 1967-10-26 | ||
US3780177A (en) * | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
US3733318A (en) | 1972-03-23 | 1973-05-15 | Syntex Corp | 21-orthoesters of cortical steroids and methods of preparing same |
JPS5910799B2 (en) * | 1975-07-15 | 1984-03-12 | 大正製薬株式会社 | Pregnane steroid 17-ester production method |
GB2109817B (en) | 1981-11-18 | 1985-07-03 | Ibm | Electrodeposition of chromium |
DE3243482A1 (en) | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW 6 (ALPHA) METHYL CORTICOIDS, THEIR PRODUCTION AND USE |
DE3402330A1 (en) | 1984-01-20 | 1985-07-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1 (ALPHA), 2 (ALPHA) -METHYLENE-6-METHYLENE AND 6 (ALPHA) -METHYL PREGNENE, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US4920216A (en) | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
US5264428A (en) * | 1990-02-16 | 1993-11-23 | Kanoldt Arzneimittel Gmbh | Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases |
JPH08135789A (en) | 1994-11-09 | 1996-05-31 | Komatsu Ltd | Transmission for vehicular hydraulic drive device and control method for the transmission |
DE19653730C2 (en) | 1996-12-11 | 1999-06-24 | Schering Ag | Immobilized proteins from crude extract and their use for the conversion of esters |
US6028208A (en) | 1997-06-25 | 2000-02-22 | Teijin Limited | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same |
EP1390377B1 (en) * | 2001-05-22 | 2006-03-08 | Pfizer Products Inc. | New crystal form of azithromycin |
WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
EP1491190A4 (en) * | 2002-03-27 | 2006-01-04 | Shionogi & Co | Decomposition inhibitor for extracellular matrix of cartilage |
ATE338763T1 (en) * | 2002-08-02 | 2006-09-15 | Schering Ag | PROGESTERONE RECEPTOR MODULATORS WITH INCREASED ANTIGONADOTROTIC ACTIVITY FOR FEMALE FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY |
CA2496867A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
JP4425921B2 (en) | 2003-03-05 | 2010-03-03 | メルク フロスト カンパニー | Nitrogen oxide releasing prodrug of diaryl 2- (5H) -furanone acting as cyclooxygenase-2 inhibitor |
US20050008704A1 (en) | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
JP2008189549A (en) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | Carboxylic acid derivative or its salt |
PE20070343A1 (en) | 2005-07-29 | 2007-05-12 | Medivir Ab | MACRO CYCLIC INHIBITORS OF HEPATITIS C VIRUS |
ITMI20051695A1 (en) * | 2005-09-14 | 2007-03-15 | Cosmo Spa | USE OF 17A-ESTERI C3-C10 OF 9,11-DEIDROCORTEXOLONE CME ANTI-GONADOTROPINIC AGENTS |
ITMI20071616A1 (en) * | 2007-08-03 | 2009-02-04 | Cosmo Spa | ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI. |
EP2648676A4 (en) | 2010-12-06 | 2016-05-04 | Follica Inc | Methods for treating baldness and promoting hair growth |
ITMI20132157A1 (en) | 2013-12-20 | 2015-06-21 | Cosmo Dermatos Srl | CORTEXOLONE 17ALFA-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. 17ALFA CORTEXOLONE-PROPIONED FOR USE IN THE TREATMENT OF SKIN WOUNDS AND / OR ATROPHIC SKIN DISORDERS. |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
-
2007
- 2007-08-03 IT IT001616A patent/ITMI20071616A1/en unknown
-
2008
- 2008-07-18 AR ARP080103135A patent/AR072235A1/en unknown
- 2008-07-24 SI SI200831538T patent/SI2503005T1/en unknown
- 2008-07-24 HU HUE12173152A patent/HUE026206T2/en unknown
- 2008-07-24 BR BRPI0814163-0A2A patent/BRPI0814163A2/en not_active Application Discontinuation
- 2008-07-24 MX MX2010001256A patent/MX2010001256A/en active IP Right Grant
- 2008-07-24 JP JP2010518628A patent/JP5646992B2/en active Active
- 2008-07-24 MX MX2014009552A patent/MX363238B/en unknown
- 2008-07-24 SI SI200832066T patent/SI2966175T1/en unknown
- 2008-07-24 PL PL12173228T patent/PL2503005T3/en unknown
- 2008-07-24 EP EP12173152.5A patent/EP2503004B1/en active Active
- 2008-07-24 PL PL08775319T patent/PL2173891T3/en unknown
- 2008-07-24 KR KR1020107003182A patent/KR101495192B1/en active IP Right Grant
- 2008-07-24 DK DK15175112.0T patent/DK2966175T3/en active
- 2008-07-24 EP EP08775319.0A patent/EP2173891B1/en active Active
- 2008-07-24 CN CN201310339201.XA patent/CN103450304B/en active Active
- 2008-07-24 CA CA2871025A patent/CA2871025C/en not_active Expired - Fee Related
- 2008-07-24 ES ES15175112T patent/ES2732326T3/en active Active
- 2008-07-24 ES ES12173152.5T patent/ES2551910T3/en active Active
- 2008-07-24 DK DK12173228.3T patent/DK2503005T3/en active
- 2008-07-24 RS RS20150723A patent/RS54361B1/en unknown
- 2008-07-24 DK DK08775319.0T patent/DK2173891T3/en active
- 2008-07-24 PL PL15175112T patent/PL2966175T3/en unknown
- 2008-07-24 EP EP19163462.5A patent/EP3521298A1/en active Pending
- 2008-07-24 EP EP15175112.0A patent/EP2966175B1/en active Active
- 2008-07-24 PT PT121731525T patent/PT2503004E/en unknown
- 2008-07-24 US US12/671,932 patent/US8785427B2/en active Active
- 2008-07-24 RS RS20150691A patent/RS54354B1/en unknown
- 2008-07-24 ES ES08775319.0T patent/ES2462946T3/en active Active
- 2008-07-24 NZ NZ600767A patent/NZ600767A/en unknown
- 2008-07-24 RS RS20140233A patent/RS53310B/en unknown
- 2008-07-24 CN CN2008800245389A patent/CN101743316B/en active Active
- 2008-07-24 RU RU2010107599/10A patent/RU2482190C2/en active
- 2008-07-24 CA CA2871039A patent/CA2871039C/en not_active Expired - Fee Related
- 2008-07-24 DK DK12173152.5T patent/DK2503004T3/en active
- 2008-07-24 WO PCT/EP2008/059702 patent/WO2009019138A2/en active Application Filing
- 2008-07-24 NZ NZ599437A patent/NZ599437A/en unknown
- 2008-07-24 CA CA2691445A patent/CA2691445C/en not_active Expired - Fee Related
- 2008-07-24 AU AU2008285784A patent/AU2008285784B2/en active Active
- 2008-07-24 NZ NZ61595308A patent/NZ615953A/en unknown
- 2008-07-24 LT LTEP15175112.0T patent/LT2966175T/en unknown
- 2008-07-24 TR TR2019/09129T patent/TR201909129T4/en unknown
- 2008-07-24 HU HUE12173228A patent/HUE026507T2/en unknown
- 2008-07-24 RS RS20190782A patent/RS58950B1/en unknown
- 2008-07-24 MX MX2014009553A patent/MX363701B/en unknown
- 2008-07-24 PT PT121732283T patent/PT2503005E/en unknown
- 2008-07-24 SI SI200831199T patent/SI2173891T1/en unknown
- 2008-07-24 PT PT87753190T patent/PT2173891E/en unknown
- 2008-07-24 EP EP12173228.3A patent/EP2503005B1/en active Active
- 2008-07-24 PT PT15175112T patent/PT2966175T/en unknown
- 2008-07-24 HU HUE15175112 patent/HUE044237T2/en unknown
- 2008-07-24 PL PL12173152T patent/PL2503004T3/en unknown
- 2008-07-24 SI SI200831528T patent/SI2503004T1/en unknown
- 2008-07-24 ES ES12173228.3T patent/ES2554934T3/en active Active
- 2008-07-24 CN CN201510158436.8A patent/CN104861023B/en active Active
-
2010
- 2010-01-26 ZA ZA2010/00587A patent/ZA201000587B/en unknown
- 2010-01-29 MX MX2019003639A patent/MX2019003639A/en active IP Right Grant
-
2011
- 2011-01-05 ZA ZA2011/00133A patent/ZA201100133B/en unknown
-
2012
- 2012-04-09 RU RU2012113839/10A patent/RU2599452C2/en active
-
2013
- 2013-05-02 JP JP2013097009A patent/JP6108944B2/en active Active
- 2013-11-07 US US14/073,928 patent/US9433628B2/en active Active
-
2014
- 2014-05-09 HR HRP20140421AT patent/HRP20140421T1/en unknown
-
2015
- 2015-09-18 JP JP2015185882A patent/JP6174645B2/en active Active
- 2015-10-19 US US14/886,774 patent/US9486458B2/en active Active
- 2015-11-03 HR HRP20151174TT patent/HRP20151174T1/en unknown
- 2015-11-30 HR HRP20151298TT patent/HRP20151298T1/en unknown
-
2016
- 2016-07-15 US US15/211,094 patent/US10159682B2/en active Active
- 2016-07-15 US US15/211,087 patent/US10166245B2/en active Active
-
2018
- 2018-04-03 AR ARP180100810A patent/AR111351A2/en unknown
- 2018-04-03 AR ARP180100811A patent/AR111202A2/en unknown
- 2018-11-19 US US16/195,083 patent/US10716796B2/en active Active
-
2019
- 2019-06-24 HR HRP20191143TT patent/HRP20191143T1/en unknown
- 2019-11-18 US US16/686,738 patent/US11207332B2/en active Active
-
2021
- 2021-11-18 US US17/455,538 patent/US11938141B2/en active Active
-
2022
- 2022-11-18 US US18/057,031 patent/US20230104965A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152154A (en) | 1961-06-24 | 1964-10-06 | Vismara Francesco Spa | 17-monoesters of 17alpha, 21-dihydroxy steroids and process for the preparation thereof |
EP1421099A1 (en) | 2001-08-10 | 2004-05-26 | Cosmo S.p.A. | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Non-Patent Citations (2)
Title |
---|
GARDI ET AL., GAZZ. CHIM. IT., vol. 63, 1963, pages 43 1 |
R. GARDI ET AL., TETRAHEDRON LETTERS, 1961, pages 448 |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015091733A1 (en) | 2013-12-20 | 2015-06-25 | Cassiopea S.P.A. | CORTEXOLONE 17α-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND/OR ATROPHIC SKIN DISORDERS |
US10993949B2 (en) | 2014-10-08 | 2021-05-04 | Cosmo Technologies Limited | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors |
US11986484B2 (en) | 2014-10-08 | 2024-05-21 | Cosmo Technologies Limited | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors |
EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
US11712443B2 (en) | 2014-10-08 | 2023-08-01 | Cosmo Technologies Limited | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors |
IL272095B2 (en) * | 2014-10-08 | 2023-04-01 | Cosmo Technologies Ltd | Cortexolone 17alpha-valerate for use in the treatment of epithelial tumor diseases |
IL272095B (en) * | 2014-10-08 | 2022-12-01 | Cosmo Technologies Ltd | Cortexolone 17alpha-valerate for use in the treatment of epithelial tumor diseases |
US10183030B2 (en) | 2014-10-08 | 2019-01-22 | Cosmo Technologies Limited | 17α,21-diesters of cortexolone for use in the treatment of tumors |
US10231980B2 (en) | 2014-10-08 | 2019-03-19 | Cosmo Technologies Ltd. | Cortexolone 17alpha-benzoate for use in the treatment of tumours |
EP3456330A1 (en) | 2014-10-08 | 2019-03-20 | Cosmo Technologies Ltd | Cortexolone 17alpha-valerate for use in the treatment of tumours |
JP2019070033A (en) * | 2014-10-08 | 2019-05-09 | コスモ・テクノロジーズ・リミテツド | COMPOSITIONS FOR USE IN TREATMENT OF TUMORS CONTAINING CORTEXOLONE 17α-VALERATE |
JP7028809B2 (en) | 2014-10-08 | 2022-03-02 | コスモ・テクノロジーズ・リミテツド | Composition for use in tumor treatment containing cortexolone 17α-valerate |
US10646497B2 (en) | 2014-10-08 | 2020-05-12 | Cosmo Technologies Limited | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors |
WO2016055533A1 (en) * | 2014-10-08 | 2016-04-14 | Cosmo Technologies Ltd | 17a,21-diesters of cortexolone for use in the treatment of tumors |
JP2021046418A (en) * | 2014-10-08 | 2021-03-25 | コスモ・テクノロジーズ・リミテツド | COMPOSITIONS FOR USE IN TREATMENT OF TUMORS COMPRISING CORTEXOLONE 17α-VALERATE |
AU2016284935B2 (en) * | 2015-06-22 | 2021-07-01 | Cassiopea S.P.A. | High concentration formulation |
US11883415B2 (en) | 2015-06-22 | 2024-01-30 | Cassiopea S.P.A. | High concentration formulation |
KR102636936B1 (en) | 2015-06-22 | 2024-02-16 | 카시오페아 에스.피.에이. | Highly concentrated formulation |
US11213531B2 (en) | 2015-06-22 | 2022-01-04 | Cassiopea S.P.A. | High concentration formulation |
RU2731564C2 (en) * | 2015-06-22 | 2020-09-04 | Кассиопея С.П.А. | Highly concentrated composition |
WO2016207778A1 (en) | 2015-06-22 | 2016-12-29 | Cassiopea S.P.A | High concentration formulation |
US10980819B2 (en) | 2015-06-22 | 2021-04-20 | Cassiopea S.P.A. | High concentration formulation |
KR20180019680A (en) * | 2015-06-22 | 2018-02-26 | 카시오페아 에스.피.에이. | High concentration formulation |
CN107979999A (en) * | 2015-06-22 | 2018-05-01 | 卡斯欧皮亚公司 | High concentrate formulation |
US10603327B2 (en) | 2015-06-22 | 2020-03-31 | Cassiopea S.P.A. | High concentration formulation |
EP3108879A1 (en) * | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
WO2022084752A1 (en) * | 2020-10-19 | 2022-04-28 | Industriale Chimica S.R.L. | Process for the production of 21-(acetyloxy)-17-(propionyloxy)-pregn-4-ene-3,20-dione |
FR3115284A1 (en) | 2020-10-19 | 2022-04-22 | Industriale Chimica S.R.L. | METHOD FOR THE PREPARATION OF 21-(ACETYLOXY)-17-(1-OXOPROPOXY)-PREGN-4-ENE-3,20-DIONE |
DE112021004932T5 (en) | 2020-10-19 | 2023-08-10 | Industriale Chimica S.R.L. | PROCESS FOR THE PREPARATION OF 21-(ACETYLOXY)-17-(1-OXOPROPOXY)-PREGN-4-EN-3,20-DIONE |
ES2943573R1 (en) * | 2020-10-19 | 2024-04-09 | Ind Chimica Srl | Process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione |
EP4071160A1 (en) | 2021-04-06 | 2022-10-12 | Farmabios S.p.A. | Process for the preparation of cortexolone 17 a-propionate and new hydrated crystalline form thereof |
IT202100008429A1 (en) | 2021-04-06 | 2022-10-06 | Farmabios Spa | Process for the preparation of cortexolone 17α-propionate and its new hydrated crystalline form |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11938141B2 (en) | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | |
AU2014233577B2 (en) | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880024538.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2691445 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 582313 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008775319 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008285784 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/001256 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 655/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010518628 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08775319 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2008285784 Country of ref document: AU Date of ref document: 20080724 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107003182 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010107599 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12671932 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0233 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: PI0814163 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100128 |